share_log

Betta Pharmaceuticals' (SZSE:300558) Earnings Have Declined Over Three Years, Contributing to Shareholders 62% Loss

Betta Pharmaceuticals' (SZSE:300558) Earnings Have Declined Over Three Years, Contributing to Shareholders 62% Loss

貝達製藥(深圳證券交易所代碼:300558)的收益在三年內有所下降,導致股東虧損62%
Simply Wall St ·  02/27 17:54

Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of Betta Pharmaceuticals Co., Ltd. (SZSE:300558) have had an unfortunate run in the last three years. Regrettably, they have had to cope with a 63% drop in the share price over that period. And over the last year the share price fell 25%, so we doubt many shareholders are delighted. Furthermore, it's down 24% in about a quarter. That's not much fun for holders.

投資股票不可避免地意味着買入一些表現不佳的公司。但是,貝達製藥有限公司(深圳證券交易所代碼:300558)的長期股東在過去三年中表現不佳。遺憾的是,在此期間,他們不得不應對股價下跌63%的局面。在過去的一年中,股價下跌了25%,因此我們懷疑許多股東是否感到高興。此外,它在大約一個季度內下降了24%。對於持有者來說,這沒什麼好玩的。

On a more encouraging note the company has added CN¥540m to its market cap in just the last 7 days, so let's see if we can determine what's driven the three-year loss for shareholders.

更令人鼓舞的是,該公司的市值在過去的7天內就增加了5.4億元人民幣,因此,讓我們看看我們能否確定導致股東三年虧損的原因。

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

引用巴菲特的話說:“船隻將在世界各地航行,但Flat Earth Society將蓬勃發展。市場上的價格和價值之間將繼續存在巨大差異...”評估公司情緒變化的一種有缺陷但合理的方法是將每股收益(EPS)與股價進行比較。

During the three years that the share price fell, Betta Pharmaceuticals' earnings per share (EPS) dropped by 15% each year. This reduction in EPS is slower than the 28% annual reduction in the share price. So it seems the market was too confident about the business, in the past. Of course, with a P/E ratio of 52.57, the market remains optimistic.

在股價下跌的三年中,貝達製藥的每股收益(EPS)每年下降15%。每股收益的下降低於股價每年28%的降幅。因此,過去市場似乎對該業務過於自信。當然,市盈率爲52.57,市場仍然樂觀。

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

下圖描述了 EPS 隨着時間的推移是如何變化的(點擊圖片可以看到確切的值)。

earnings-per-share-growth
SZSE:300558 Earnings Per Share Growth February 27th 2024
深圳證券交易所:300558 每股收益增長 2024 年 2 月 27 日

We know that Betta Pharmaceuticals has improved its bottom line lately, but is it going to grow revenue? You could check out this free report showing analyst revenue forecasts.

我們知道貝塔製藥最近提高了利潤,但它會增加收入嗎?您可以查看這份顯示分析師收入預測的免費報告。

A Different Perspective

不同的視角

We regret to report that Betta Pharmaceuticals shareholders are down 25% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 17%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 0.9% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, we've discovered 1 warning sign for Betta Pharmaceuticals that you should be aware of before investing here.

我們遺憾地報告,貝達製藥的股東今年下跌了25%(甚至包括股息)。不幸的是,這比整個市場17%的跌幅還要嚴重。話雖如此,在下跌的市場中,一些股票不可避免地會被超賣。關鍵是要密切關注基本發展。不幸的是,去年的表現可能預示着尚未解決的挑戰,因爲它比過去五年0.9%的年化虧損還要糟糕。總的來說,長期股價疲軟可能是一個壞兆頭,儘管逆勢投資者可能希望研究該股以期出現轉機。儘管市場狀況可能對股價產生的不同影響值得考慮,但還有其他因素更爲重要。例如,我們發現了Betta Pharmicals的1個警告信號,在這裏投資之前你應該注意這個信號。

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

如果你像我一樣,那麼你不會想錯過這份業內人士正在收購的成長型公司的免費名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論